Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

2.3%

6 terminated/withdrawn out of 261 trials

Success Rate

88.7%

+2.2% vs industry average

Late-Stage Pipeline

16%

43 trials in Phase 3/4

Results Transparency

6%

3 of 47 completed trials have results

Key Signals

31 recruiting3 with results5 withdrawn

Enrollment Performance

Analytics

N/A
69(37.3%)
Phase 2
48(25.9%)
Phase 4
35(18.9%)
Phase 1
20(10.8%)
Phase 3
8(4.3%)
Early Phase 1
5(2.7%)
185Total
N/A(69)
Phase 2(48)
Phase 4(35)
Phase 1(20)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (261)

Showing 20 of 261 trials
NCT06562803Not ApplicableRecruiting

Efficacy and Safety of Cytokine Adsorption and Plasma Exchange in Patients With ACLF and Sepsis

Role: lead

NCT07130968Enrolling By Invitation

Real-World Cohort Study of Cardiopulmonary Function in Chinese Patients With Cardiovascular Disease: CPET Evaluation and Five-Year Prognostic Follow-Up Based on a Multicenter Structured Data Platform

Role: collaborator

NCT07543783Phase 2Not Yet Recruiting

Efficacy and Safety of Low-dose Bevacizumab Plus Adebrelimab Combined With Transarterial Chemoembolization Followed by Hepatic Arterial Infusion Chemotherapy (TACE-HAIC) as First-line Treatment for Unresectable Hepatocellular Carcinoma: A Single-arm Phase 2 Trial

Role: lead

NCT06140992Recruiting

PaCIFiC-CUP Classifies Cancer of Unknown Primary

Role: collaborator

NCT07543510Not ApplicableNot Yet Recruiting

Low-Dose Bevacizumab and Atezolizumab Combined With TACE-HAIC in Unresectable Hepatocellular Carcinoma

Role: lead

NCT06966908Recruiting

Hospital-Based Management of Patients With Chronic Hepatitis B Virus Infection

Role: lead

NCT07502729Not Yet Recruiting

Optimizing Endoscopic and Interventional Treatment for Portal Hypertensive Bleeding

Role: collaborator

NCT07409259Early Phase 1Active Not Recruiting

PT-MSCs Exosome Injection in the Treatment of Chronic-to-acute Liver Failure

Role: lead

NCT07354997Not ApplicableCompleted

Establishing a Virtual Health Community Management Model for Pre-Diabetes Patients

Role: lead

NCT07373691Enrolling By Invitation

A Study on Multimodal Prognostic Scoring of Advanced PDAC.

Role: collaborator

NCT07353216Recruiting

Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels

Role: lead

NCT07338552Not ApplicableNot Yet Recruiting

Effectiveness of a Virtual Health Management Community (VHMC) for Pre-diabetes in China

Role: lead

NCT07314749Not ApplicableCompleted

2025 Hypoglycemia Early-Warning and Physician-Nurse Collaborative Management Trial in Type 2 Diabetes

Role: lead

NCT07291804Not ApplicableCompleted

Efficacy and Safety of an Intelligent Insulin-Dosing Decision Support System for Glycemic Control in Patients With Type 2 Diabetes: A Randomized Controlled Study

Role: lead

NCT07281664Not ApplicableNot Yet Recruiting

Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

Role: lead

NCT07157631Not ApplicableRecruiting

Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial

Role: collaborator

NCT07253233Early Phase 1Not Yet Recruiting

Treatment of Spinal Cord Injury Using Autologous Concentrated Growth Factors

Role: lead

NCT06976229Phase 1Recruiting

Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial

Role: collaborator

NCT06974968Phase 2Not Yet Recruiting

Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial

Role: collaborator

NCT04896255Recruiting

Long-term Outcomes of Anti-viral Therapies in Patients With Chronic Viral Hepatitis B

Role: collaborator